

PERSONAL INFORMATION

Francesca Maria Gay

CURRENT POSITION

Associate Professor, Department of Molecular Biotechnology and Health Sciences, University of Torino, "SC Ematologia U" Division, at AOU Città della Salute e della Scienza di Torino, Turin, Italy

STUDIES AND TITLES

Medical Doctor (2004)  
Hematologist (2008)  
PhD in Medicine and Experimental Therapy (2014)

WORK EXPERIENCE

- December 2019-to date** Associate Professor, Department of Molecular Biotechnology and Health Sciences, University of Torino, "SC Ematologia U" Division, at AOU Città della Salute e della Scienza di Torino, Turin, Italy
- December 2010-December 2019** 1st Level Head Physician at the "SC Ematologia U" Division, in Prof. Mario Boccardo's team, at AOU Città della Salute e della Scienza di Torino, Turin, Italy.
- October 2009-November 2010** Clinical research and assistance to multiple myeloma patients, at the "SC Ematologia U" Division, in Prof. Mario Boccardo's team, at AOU Città della Salute e della Scienza di Torino, Turin, Italy
- February 2009-September 2009** Clinical research at Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN, USA

EDUCATION AND TRAINING

- January 2011-December 2014** PhD in Medicine and Experimental Therapy  
Università degli Studi di Torino (UNITO), Turin – Italy
- Academic years 2005-2008** Specialization School in Hematology  
Università degli Studi di Torino (UNITO), Turin - Italy  
Hematology specialization obtained on December 23, 2008; final grade: 70/70 cum laude
- March 2005** MD license to practice and inclusion into the MD professional registry of Turin - Italy  
On March 7, 2005 (MD professional registry identification number: 20427)
- Academic years 1998-2004** Faculty of Medicine and Surgery,  
Università degli Studi di Torino (UNITO), Turin - Italy  
Degree obtained on July 14, 2004; final grade: 110/110 cum laude
- September 1993-June 1998** Scientific High School (PNI – mathematics and informatics specialization)  
Scientific High School "Aldo Moro", Rivarolo C.se –Turin, Italy  
High school diploma; final grade: 60/60

PERSONAL SKILLS

**Mother tongue** Italian

**Other languages**

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Interaction	Production	
English	C1	C1	C1	C1	C1

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user  
[Common European Framework of Reference for Languages](#)

## Job-related skills

- Clinical research skills, in particular in the field of multiple myeloma, working with the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and the European Myeloma Network (EMN).
- Scientific activities for the diagnosis and treatment of myeloma patients using new biological molecules and/or monoclonal antibodies; participation in various national and international clinical trials about lymph-proliferative and plasma cell disorders (Phase I, II, III)
- Principal Investigator of the phase III study RV-MM-PI-441 (cyclophosphamide, lenalidomide and dexamethasone versus melphalan 200 mg/m<sup>2</sup>- ASCT and lenalidomide-prednisone [RP] vs lenalidomide [R] maintenance);
- Medical monitor of the phase II FORTE (Carfilzomib Combined with Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Desametasone (CRd) Followed by ASCT or 12 Cycles of Carfilzomib Combined with Dexamethasone and Lenalidomide for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma) and of the Phase III PERSEUS (Daratumumab, VELCADE® (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE®, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma);
- Co-principal Investigator, and medical monitor of the phase I/II EMN09 (Carfilzomib in Combination with Bendamustine and dexamethasone in Refractory or Relapsed Multiple Myeloma);
- Member of the data safety monitoring committee dello studio HOVON 123-MM (Feasibility and Efficacy of Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) in Elderly Patients ≥75 Years of Age with Newly Diagnosed Multiple Myeloma: A Non-Randomised Phase II Study).
- Local Principal Investigator (PI) and sub-investigator in several Clinical studies.
- Participation in - and organization of - inter-divisional groups (GIC) to discuss complex clinical cases regarding patients with multiple myeloma, plasma cell leukemia, and amyloidosis.
- Activities as hematology specialist, including diagnosis and treatment of hematologic patients, in particular those with lymph-proliferative and plasma cell disorders; outpatient activities and diagnostic assessment (including bone biopsies and marrow aspirates), as well as therapeutic and follow-up evaluation of patients, including bureaucratic matters; day hospital activities, including defining chemotherapy cycles and treatment schedules; clinical evaluation of onco-hematologic patients, assessment of test results in terms of remission and adverse events; consulting activities; inter-divisional doctor on call.
- Teaching activities to - and supervision of - medical students, as well as residents and fellows, during their internship/training period (outpatient, day hospital and care unit).

## Driving License B

ADDITIONAL INFORMATION

<b>Publications</b>	<p>99 publications on national and international journals; H index 30 (source: Scopus, March 27, 2020). 3 Book Chapters (see the complete list in Attachment A).</p> <p>Reviewer for different international, scientific journals (such as Lancet, Blood, Leukemia, Lancet Hematology, Clinical cancer research, Hematologica, Oncotarget, Journal of Cancer, Annals of Hematology, Expert Opinion on Pharmacotherapy, American Journal of Hematology, Advances in Cell and Gene therapies, European Journal of Hematology, British journal of hematology, Clinical Lymphoma, Myeloma and Leukemia, Oncotargets and Therapy, Cancer Management and Research, Journal of Oncology, Expert Review on Proteomics, Transfusion and Apheresis Science); Frontiers in Oncology.</p> <p>Member of the Editorial Board of HemaSphere.</p>
<b>Presentations</b>	<p>Speaker in different congresses/seminars, including oral presentations at national (SIE) and international congresses (EHA, ASCO, ASH, IMW, ECCO, IMS, ESH, HEMO, BSH, KSH). (Attachments B and C)</p> <p>Reviewer to select abstract at the following congresses: International Myeloma Workshop (2015, 2017,2019); European Hematology Association (2013, 2016, 2020); American Society of Hematology (2011, 2012,2019). Moderator in some sessions of the above congresses.(Attachments B and C)</p>
<b>Grant Support participation</b>	<p>Participant in the project "Minimal residual disease to better characterize multiple myeloma response and detect early relapse", for the grant "Multiple Myeloma Research Foundation - MMRF 2010".</p> <p>Bart Barlogie Young Investigation Award, Grant from IMS (sept 2019)</p>
<b>Professional societies</b>	<p>EHA, EMN, IMS, ASH, SIE</p> <p>Member of the EHA SC advisory board (2019-2020)</p> <p>Member of the Educational committee of IMS (2020)</p>
<b>Meetings/Seminars/Courses</b>	<p>Participation in several meetings, seminars and courses (Complete list in Attachment C), and advisory boards.</p>
<b>Clinical Trial Experience</b>	<p>Experience in studies of phase I, II, III concerning multiple myeloma</p>
<b>ICH-GCP Training</b>	<p>ICH-GCP training attended for previous clinical trials</p> <p>GCP certification validated by TransCelerate done on 21 Nov 2016</p> <p>GCP certification (E6 - R2) validated by TransCelerate done on October 16, 2017.</p>
<b>Scientific interests</b>	<p>Multiple Myeloma</p> <ul style="list-style-type: none"> <li>- efficacy of high-dose versus conventional chemotherapy</li> <li>- role of prognostic factors</li> <li>- immunosurveillance and immunotherapy</li> <li>- molecular alterations and minimal residual disease</li> </ul>

Attachments

- 
- A. Publications.**
  - B. Oral and poster presentations, national and International Meetings (first/presenting author).**
  - C. Other presentations and complete meeting list (national and international meetings, patient seminars).**

Turin, March 27, 2020

Dr. Francesca Gay



## Attachment A. List of publications

### INTERNATIONAL JOURNALS

1. D'Agostino, M., Mina, R., & **Gay, F.** (2020). Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen? *The Lancet Haematology*. Ahead of print. doi: 10.1016/s2352-3026(19)30254-6
2. Bonello, F., Mina, R., Boccadoro, M., & **Gay, F.** (2020, January 1). Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma. *Cancers*, Vol. 12. doi: 10.3390/cancers12010015
3. Ghisoni, E., Marandino, L., Lombardi, P., Bonzano, A., Becco, P., Aglietta, M., **Gay, F.**, ... Rota Scalabrini, D. (2019). Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report. *Acta Haematologica*. doi: 10.1159/000502538
4. Bonello, F., Pulini, S., Ballanti, S., Gentile, M., Spada, S., Annibali, O., ... **Gay, F.** (2019). Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis. *Cancers*, 11(11). doi: 10.3390/cancers11111735
5. D'agostino, M., Bertamini, L., Oliva, S., Boccadoro, M., & **Gay, F.** (2019, December 1). Pursuing a curative approach in multiple myeloma: A review of new therapeutic strategies. *Cancers*, Vol. 11. doi: 10.3390/cancers11122015
6. Montefusco, V., **Gay, F.**, Spada, S., de Paoli, L., Raimondo, F. Di, Ribolla, R., ... Boccadoro, M. (2020). Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. *Haematologica*, 105(1), 193–200. doi: 10.3324/haematol.2019.219139
7. Bruno, G., Bringhen, S., Maffei, I., Iannaccone, A., Crea, T., Ravera, A., ..., **Gay, F.**, ... Milan, A. (2019). Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy. *Cancers*, 11(5), 622. <https://doi.org/10.3390/cancers11050622>. Impact Factor - ultimo dato disponibile (fonte in InCites Journal Citation Reports, 27/5/2019) [IF]: 5,326. Cited by (Web of Science All Databases, 24/5/2019) [WoS AD]: 0. Cited by (Web of Science Core Collection, 27/5/2019). Cited by (Scopus, 30/5/2019).
8. Plesner, T., Arkenau, H., **Gay, F.**, Minnema, M. C., Boccadoro, M., Moreau, P., ... Richardson, P. G. (2019). Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN 503): final results of an open-label, phase 1/2 study. *British Journal of Haematology*, bjh.15879. <https://doi.org/10.1111/bjh.15879>. IF 5,128. Cited by: WoS AD 0; Sc 0.
9. **Gay, F.** & Mina R. (2019). Redefining the treatment paradigm for multiple myeloma. *The Lancet Oncology*, Epub ahead of print. [https://doi.org/10.1016/S1470-2045\(19\)30295-5](https://doi.org/10.1016/S1470-2045(19)30295-5). IF 36,421. Cited by: WoS AD 0.
10. Castella, B., Mina, R., & **Gay, F.** (2019). CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab. *Cytometry Part A*, 95(4), 416–418. <https://doi.org/10.1002/cyto.a.23752>. IF 3,260. Cited by: WoS AD 0; WoS CC 0; Sc 0.
11. **Gay, F.**, & Goldschmidt, H. (2019). Do we need cytogenetics in the follow-up of multiple myeloma? *British Journal of Haematology*, 185(3), 399–401. <https://doi.org/10.1111/bjh.15781>. IF 5,128. Cited by: WoS AD 0; WoS CC 0; Sc 0.
12. Bringhen, S., Milan, A., D'Agostino, M., Ferri, C., Wäsch, R., **Gay, F.**, ... Engelhardt, M. (2019). Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *Journal of Internal Medicine*, joim.12882. <https://doi.org/10.1111/joim.12882>. IF 6,754. Cited by: WoS AD 0; Sc 0.
13. Iannaccone, A., Bruno, G., Ravera, A., **Gay, F.**, Salvini, M., Bringhen, S., ... Milan, A. (2018). Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. *High Blood Pressure & Cardiovascular Prevention*, 25(2), 209–218. <https://doi.org/10.1007/s40292-018-0256-1>. Cited by: WoS AD 0; WoS CC 0; Sc 1.

14. D'Agostino, M., De Paoli, L., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., ... **Gay, F.** (2018). Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. *Critical Reviews in Oncology/Hematology*, 132, 9–16. <https://doi.org/10.1016/j.critrevonc.2018.09.008>. IF 4,495. Cited by: WoS AD 1; WoS CC 1; Sc 1.
15. **Gay, F.**, Jackson, G., Rosiñol, L., Holstein, S. A., Moreau, P., Spada, S., ... Attal, M. (2018). Maintenance Treatment and Survival in Patients with Myeloma. A Systematic Review and Network Meta-analysis. *JAMA Oncology*, 4(10), 1389-1397. <https://doi.org/10.1001/jamaoncol.2018.2961>. IF 20,871. Cited by: WoS AD 8; WoS CC 8; Sc 8.
16. Dimopoulos, M. A., **Gay, F.**, Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., ... Janakiram, M. (2019). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. *The Lancet*, 393(10168), 253–264. [https://doi.org/10.1016/S0140-6736\(18\)33003-4](https://doi.org/10.1016/S0140-6736(18)33003-4). IF 53,254. Cited by: WoS AD 2; WoS CC 2; Sc 6.
17. Cerrato, C., Di Raimondo, F., De Paoli, L., Spada, S., Patriarca, F., Crippa, C., ... **Gay, F.** (2018). Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. *Journal of Cancer Research and Clinical Oncology*, 144(7), 1357–1366. <https://doi.org/10.1007/s00432-018-2641-5>. IF 3,282. Cited by: WoS AD 1; WoS CC 1; Sc 2.
18. Nanni, C., Versari, A., Chauvie, S., Bertone, E., Bianchi, A., Rensi, M., ..., **Gay, F.**, ... Zamagni, E. (2018). Interpretation criteria for FDG PET/CT in multiple myeloma (IMPETUs): final results. IMPETUs (Italian myeloma criteria for PET USE). *European Journal of Nuclear Medicine and Molecular Imaging*, 45(5), 712–719. <https://doi.org/10.1007/s00259-017-3909-8>. IF 7,704. Cited by: WoS AD 9; WoS CC 11; Sc 11.
19. Bonello, F., D'Agostino, M., Moscvin, M., Cerrato, C., Boccadoro, M., & **Gay, F.** (2018). CD38 as an immunotherapeutic target in multiple myeloma. *Expert Opinion on Biological Therapy*, 18(12), 1209–1221. <https://doi.org/10.1080/14712598.2018.1544240>. IF 3,974. Cited by: WoS AD 0; WoS CC 0; Sc 0.
20. **Gay, F.**, & Larocca, A. (2018). Special problems in the management of elderly patients with multiple myeloma. *European Journal of Internal Medicine*, 58, 64–69. <https://doi.org/10.1016/j.ejim.2018.05.027>. IF 3,282. Cited by: WoS AD 0; WoS CC 0; Sc 0.
21. Oliva, S., Troia, R., D'Agostino, M., Boccadoro, M., & **Gay, F.** (2018). Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. *Frontiers in Immunology*, 9. <https://doi.org/10.3389/fimmu.2018.02749>. IF 5,511. Cited by: WoS AD 1; WoS CC 1; Sc 1.
22. Bringhen, S., Milan, A., Ferri, C., Wäsch, R., **Gay, F.**, Larocca, A., ... Engelhardt, M. (2018). Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). *Haematologica*, 103(9), 1422–1432. <https://doi.org/10.3324/haematol.2018.191288>. IF 9,090. Cited by: WoS AD 2; WoS CC 3; Sc 3.
23. D'Agostino, M., Gazzera, G., Cetani, G., Bringhen, S., Boccadoro, M., & **Gay, F.** (2018). Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. *Current Medicinal Chemistry*, 25. <https://doi.org/10.2174/0929867325666180514114806>. IF 3,460. Cited by: WoS AD 1.
24. Leleu, X., **Gay, F.**, Flament, A., Allcott, K., & Delforge, M. (2018). Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate? *Annals of Hematology*, 97(3), 387–400. <https://doi.org/10.1007/s00277-017-3191-7>. IF 2,845. Cited by: WoS AD 1; WoS CC 1; Sc 1.
25. **Gay, F.**, Engelhardt, M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., ... Sonneveld, P. (2018). From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. *Haematologica*, 103(2), 197–211. <https://doi.org/10.3324/haematol.2017.174573>. IF 9,090. Cited by: WoS AD 23; WoS CC 21; Sc 22.
26. Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastiris, E., van de Donk, N., ..., **Gay, F.**, ... Terpos, E. (2018). European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia*, 32(9), 1883–1898. <https://doi.org/10.1038/s41375-018-0209-7>. IF 10,023. Cited by: WoS AD 8; WoS CC 8; Sc 9.
27. Caers, J., Garderet, L., Kortüm, K. M., O'Dwyer, M. E., van de Donk, N. W. C. J., Binder, M., ..., **Gay, F.**, ... Engelhardt, M. (2018). European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. *Haematologica*, 103(11), 1772–1784. <https://doi.org/10.3324/haematol.2018.189159>. IF 9,090. Cited by: WoS AD 3; WoS CC 3; Sc 4.

28. Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D'Agostino, M., ..., **Gay, F.**, ... Engelhardt, M. (2018). Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). *Leukemia*, 32(8), 1697–1712. <https://doi.org/10.1038/s41375-018-0142-9>. IF 10,023. Cited by: WoS AD 5; WoS CC 5; Sc 8.
29. Ludwig, H., Delforge, M., Facon, T., Einsele, H., **Gay, F.**, Moreau, P., ... Sonneveld, P. (2018). Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia*, 32(7), 1542–1560. <https://doi.org/10.1038/s41375-018-0040-1>. IF 10,023. Cited by: WoS AD 5; WoS CC 5; Sc 9.
30. **Gay, F.**, Oliva, S., Petrucci, M. T., Montefusco, V., Conticello, C., Musto, P., ... Boccadoro, M. (2017). Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. *Leukemia*, 31(8), 1727–1734. <https://doi.org/10.1038/leu.2016.381>. IF 10,023. Cited by: WoS AD 12; WoS CC 12; Sc 16.
31. Offidani, M., Corvatta, L., Bringhen, S., Gentili, S., Troia, R., Maracci, L., ..., **Gay, F.**, ... Boccadoro, M. (2017). Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. *EUROPEAN JOURNAL OF HAEMATOLOGY*, 98(3), 289–295. <https://doi.org/10.1111/ejh.12834>. IF 2,594. Cited by: WoS AD 1; WoS CC 1; Sc 1.
32. Oliva, S., Gambella, M., Gilestro, M., Muccio, V. E., **Gay, F.**, Drandi, D., ... Omedè, P. (2017). Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. *Oncotarget*, 8(4), 5924–5935. <https://doi.org/10.18632/oncotarget.12641>. IF 5,168. Cited by: WoS AD 11; WoS CC 11; Sc 9.
33. Gentile, M., Magarotto, V., Offidani, M., Musto, P., Bringhen, S., Teresa Petrucci, M., ..., **Gay, F.**, ... Morabito, F. (2017). Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. *American Journal of Hematology*, 92(3), 244–250. <https://doi.org/10.1002/ajh.24621>. IF 5,303. Cited by: WoS AD 4; WoS CC 5; Sc 4.
34. McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., ..., **Gay, F.**, ... Attal, M. (2017). Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 35(29), 3279–3289. <https://doi.org/10.1200/JCO.2017.72.6679>. IF 26,360. Cited by: WoS AD 76; WoS CC 75; Sc 89.
35. Mina, R., D'Agostino, M., Cerrato, C., **Gay, F.**, & Palumbo, A. (2017). Plasma cell leukemia: update on biology and therapy. *LEUKEMIA & LYMPHOMA*, 58(7), 1538–1547. <https://doi.org/10.1080/10428194.2016.1250263>. IF 2,644. Cited by: WoS AD 9; WoS CC 9; Sc 8.
36. D'Agostino, M., Salvini, M., Palumbo, A., Larocca, A., & **Gay, F.** (2017). Novel investigational drugs active as single agents in multiple myeloma. *EXPERT OPINION ON INVESTIGATIONAL DRUGS*, 26(6), 699–711. <https://doi.org/10.1080/13543784.2017.1324571>. IF 3,883. Cited by: WoS AD 3; WoS CC 3; Sc 3.
37. Offidani, M., Gentili, S., **Gay, F.**, Aghemo, E., Maracci, L., Corvatta, L., & Palumbo, A. (2017). Stem Cell Transplantation in Multiple Myeloma. *CURRENT CANCER DRUG TARGETS*, 17(9), 769–781. <https://doi.org/10.1174/1568009616666160910090136>. IF 2,626. Cited by: WoS AD 0; WoS CC 0; Sc 0.
38. Kumar, S. K., Rajkumar, V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M.-V., ..., **Gay, F.**, ... Anderson, K. C. (2017). Multiple myeloma. *NATURE REVIEWS DISEASE PRIMERS*, 3. <https://doi.org/10.1038/nrdp.2017.46>. IF 16,071. Cited by: WoS AD 75; WoS CC 73; Sc 86.
39. Larocca, A., Mina, R., **Gay, F.**, Bringhen, S., ... Boccadoro, M., (2017). Emerging drugs and combinations to treat multiple myeloma. *Oncotarget*, 5(0). <https://doi.org/10.18632/oncotarget.19269>. IF 5,168. Cited by: WoS AD 13; WoS CC 11; Sc 15.
40. **Gay, F.**, D'Agostino, M., Giaccone, L., Genuardi, M., Festuccia, M., Boccadoro, M., & Bruno, B. (2017). Immunologic Approaches: CAR-T Cells and Checkpoint Inhibitors. *Clinical Lymphoma, Myeloma & Leukemia*, 17(8), 471–478. <https://doi.org/10.1016/j.clml.2017.06.014>. IF 2,308. Cited by: WoS AD 9; WoS CC 7; Sc 9.
41. **Gay, F.**, Genuardi, M., & Boccadoro, M. (2017). Autologous transplant for myeloma: when the old meets the new. *ONCOTARGET*, 8(53), 90618–90619. <https://doi.org/10.18632/oncotarget.21605>. IF 5,168. Cited by: WoS AD 0; WoS CC 0; Sc 0.

42. Zamagni, E., Nanni, C., **Gay, F.**, Pezzi, A., Patriarca, F., Bellò, M., ... Cavo, M. (2016). 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. *Leukemia*, 30(2), 417–22. <https://doi.org/10.1038/leu.2015.291>. IF 10,023. Cited by: WoS AD 35; WoS CC 37; Sc 43.
43. Fouquet, G., **Gay, F.**, Boyle, E., Bringhen, S., Larocca, A., Facon, T., ... Palumbo, A. (2016). Treatment of Newly Diagnosed Elderly Multiple Myeloma. *Cancer Treatment and Research*, 169, 123–143. [https://doi.org/10.1007/978-3-319-40320-5\\_8](https://doi.org/10.1007/978-3-319-40320-5_8). Cited by: WoS AD 2; Sc 2.
44. Pawlyn, C.,\* **Gay, F.**,\* Larocca, A., Roy, V., & Ailawadhi, S. (2016). Nuances in the Management of Older People With Multiple Myeloma. *CURRENT HEMATOLOGIC MALIGNANCY REPORTS*, 11(3), 241–251. <https://doi.org/10.1007/s11899-016-0323-4> (\*Share the first authorship). IF 2,338. Cited by: WoS AD 6; WoS CC 7; Sc 7.
45. van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A., **Gay, F.**, Laubach, J. P., ... Richardson, P. G. (2016). Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. *Blood*, 127(6), 681–695. <https://doi.org/10.1182/blood-2015-10-646810>. IF 15,132. Cited by: WoS AD 83; WoS CC 83; Sc 98.
46. Nanni, C., Zamagni, E., Versari, A., Chauvie, S., Bianchi, A., Rensi, M., ..., **Gay, F.**, ... Fanti, S. (2016). Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USE). *European Journal of Nuclear Medicine and Molecular Imaging*, 43(3), 414–421. <https://doi.org/10.1007/s00259-015-3200-9>. IF 7,704. Cited by: WoS AD 27; WoS CC 27; Sc 31.
47. Musto, P., Simeon, V., Grossi, A., **Gay, F.**, Bringhen, S., Larocca, A., ... Boccadoro, M. (2015). Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. *STEM CELL RESEARCH & THERAPY*, 6. <https://doi.org/10.1186/s13287-015-0033-1>. IF 4,963. Cited by: WoS AD 3; WoS CC 4; Sc 5.
48. Palumbo, A., **Gay, F.**, Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., ... Boccadoro, M. (2015). Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 33(30), 3459–66. <https://doi.org/10.1200/JCO.2014.60.2466>. IF 26,360. Cited by: WoS AD 58; WoS CC 57; Sc 65.
49. Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., ..., **Gay, F.**, ... Moreau, P. (2015). Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 33(26), 2863–9. <https://doi.org/10.1200/JCO.2015.61.2267>. IF 26,360. Cited by: WoS AD 357; WoS CC 331; Sc 367.
50. **Gay, F.**, Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., ... Palumbo, A. (2015). Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. *The Lancet Oncology*, 16(16), 1617–29. [https://doi.org/10.1016/S1470-2045\(15\)00389-7](https://doi.org/10.1016/S1470-2045(15)00389-7). IF 36,421. Cited by: WoS AD 106; WoS CC 103; Sc 117.
51. **Gay, F.**, Cavallo, F., & Palumbo, A. (2015). The Role of Pre-Transplant Induction Regimens and Autologous Stem Cell Transplantation in the Era of Novel Targeted Agents. *DRUGS*, 75(4), 367–375. <https://doi.org/10.1007/s40265-015-0367-0>. IF 4,690. Cited by: WoS AD 3; WoS CC 2; Sc 2.
52. **Gay, F.**, & Palumbo, A. (2015). Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective? *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*, 21(10), 1705–1706. <https://doi.org/10.1016/j.bbmt.2015.08.005>. IF 4,484. Cited by: WoS AD 0; WoS CC 0; Sc 0.
53. Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., **Gay, F.**, Kastritis, E., ... European Myeloma Network. (2015). European Myeloma Network guidelines for the management of multiple myeloma-related complications. *Haematologica*, 100(10), 1254–66. <https://doi.org/10.3324/haematol.2014.117176>. IF 9,090. Cited by: WoS AD 111; WoS CC 108; Sc 120.
54. Palumbo, A., Cavallo, F., **Gay, F.**, Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., ... Cavo, M. (2014). Autologous transplantation and maintenance therapy in multiple myeloma. *The New England Journal of Medicine*, 371(10), 895–905. <https://doi.org/10.1056/NEJMoa1402888>. IF 79,260. Cited by: WoS AD 305; WoS CC 296; Sc 318.

55. Festuccia, M., Giaccone, L., **Gay, F.**, Brunello, L., Maffini, E., Ferrando, F., ... Bruno, B. (2014). Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report. *Transplant Infectious Disease: An Official Journal of the Transplantation Society*, 16(4), 653–7. <https://doi.org/10.1111/tid.12245>. IF 1,869. Cited by: WoS AD 2; WoS CC 2; Sc 2.
56. Gambella, M., Rocci, A., Passera, R., **Gay, F.**, Omede, P., Crippa, C., ... Palumbo, A. (2014). High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. *HAEMATOLOGICA*, 99(2), E14–E16. <https://doi.org/10.3324/haematol.2013.090142>. IF 9,090. Cited by: WoS AD 21; WoS CC 20; Sc 20.
57. Rocci, A., Gambella, M., Aschero, S., Baldi, I., Trusolino, L., Cavallo, F., ..., **Gay, F.**, ... Palumbo, A. (2014). MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. *BRITISH JOURNAL OF HAEMATOLOGY*, 164(6), 841–850. <https://doi.org/10.1111/bjh.12719>. IF 5,128. Cited by: WoS AD 11; WoS CC 11; Sc 13.
58. Caltagirone, S., Ruggeri, M., Aschero, S., Gilestro, M., Oddolo, D., **Gay, F.**, ... Omede, P. (2014). Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. *HAEMATOLOGICA*, 99(10), 1611–1617. <https://doi.org/10.3324/haematol.2014.103853>. IF 9,090. Cited by: WoS AD 12; WoS CC 10; Sc 11.
59. Donato, F., **Gay, F.**, Bringhen, S., Troia, R., & Palumbo, A. (2014). Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. *EXPERT OPINION ON BIOLOGICAL THERAPY*, 14(8), 1127–1144. <https://doi.org/10.1517/14712598.2014.908848>. IF 3,974. Cited by: WoS AD 9; WoS CC 9; Sc 11.
60. Bringhen, S., **Gay, F.**, Donato, F., Troia, R., Mina, R., & Palumbo, A. (2014). Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. *EXPERT OPINION ON INVESTIGATIONAL DRUGS*, 23(9), 1193–1209. <https://doi.org/10.1517/13543784.2014.920821>. IF 3,883. Cited by: WoS AD 4; WoS CC 3; Sc 6.
61. Engelhardt, M., Terpos, E., Kleber, M., **Gay, F.**, Waesch, R., Morgan, G., ... Network, E. M. (2014). European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *HAEMATOLOGICA*, 99(2), 232–242. <https://doi.org/10.3324/haematol.2013.099358>. IF 9,090. Cited by: WoS AD 117; WoS CC 109; Sc 119.
62. van de Donk, N. W. C. J., Palumbo, A., Johnsen, H. E., Engelhardt, M., **Gay, F.**, Gregersen, H., ... Network, E. M. (2014). The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. *HAEMATOLOGICA*, 99(6), 984–996. <https://doi.org/10.3324/haematol.2013.100552>. IF 9,090. Cited by: WoS AD 35; WoS CC 35; Sc 50.
63. Falco, P., Cavallo, F., Larocca, A., Rossi, D., Guglielmelli, T., Rocci, A., ... Palumbo, A. (2013). Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. *Leukemia*, 27(3), 695–701. <https://doi.org/10.1038/leu.2012.271>. IF 10,023. Cited by: WoS AD 23; WoS CC 23; Sc 24.
64. Palumbo, A., Waage, A., Hulin, C., Beksac, M., Zweegman, S., **Gay, F.**, ... Sonneveld, P. (2013). Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. *Haematologica*, 98(1), 87–94. <https://doi.org/10.3324/haematol.2012.067058>. IF 9,090. Cited by: WoS AD 45; WoS CC 45; Sc 46.
65. **Gay, F.**, Magarotto, V., Crippa, C., Pescosta, N., Guglielmelli, T., Cavallo, F., ... Palumbo, A. (2013). Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. *Blood*, 122(8), 1376–83. <https://doi.org/10.1182/blood-2013-02-483073>. Erratum in (2014) *Blood*, 123(24), 3843. . IF 15,132. Cited by: WoS AD 50; WoS CC 9; Sc 47.
66. **Gay, F.**, Mina, R., Troia, R., & Bringhen, S. (2013). Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. *EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY*, 9(11), 1517–1527. <https://doi.org/10.1517/17425255.2013.827169>. IF 3,151. Cited by: WoS AD 8; WoS CC 8; Sc 9.
67. Kumar, S. K., Lacy, M. Q., Dispenzieri, A., Buadi, F. K., Hayman, S. R., Dingli, D., ..., **Gay, F.**, ... Gertz, M. A. (2012). Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. *CANCER*, 118(6), 1585–1592. <https://doi.org/10.1002/cncr.26422>. IF 6,537. Cited by: WoS AD 65; WoS CC 63; Sc 75.
68. Bringhen, S., **Gay, F.**, Pautasso, C., Cerrato, C., Boccadoro, M., & Palumbo, A. (2012). Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.



- EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY*, 8(9), 1209–1222. <https://doi.org/10.1517/17425255.2012.712685>. IF 3,151. Cited by: WoS AD 8; WoS CC 7; Sc 7.
69. Guglielmelli, T., Bringhen, S., Rrodhe, S., **Gay, F.**, Cavallo, F., Berruti, A., ... Palumbo, A. (2011). Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. *European Journal of Cancer (Oxford, England: 1990)*, 47(6), 814–8. <https://doi.org/10.1016/j.ejca.2010.12.026>. IF 7,191. Cited by: WoS AD 11; WoS CC 10; Sc 14.
70. Benevolo, G., Larocca, A., Gentile, M., Pregno, P., **Gay, F.**, Botto, B., ... Palumbo, A. (2011). The Efficacy and Safety of Bortezomib and Dexamethasone as a Maintenance Therapy in Patients With Advanced Multiple Myeloma Who Are Responsive to Salvage Bortezomib-Containing Regimens. *CANCER*, 117(9), 1884–1890. <https://doi.org/10.1002/cncr.25743>. IF 6,537. Cited by: WoS AD 12; WoS CC 10; Sc 12.
71. **Gay, F.**, Larocca, A., Wijermans, P., Cavallo, F., Rossi, D., Schaafsma, R., ... Palumbo, A. (2011). Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. *Blood*, 117(11), 3025–31. <https://doi.org/10.1182/blood-2010-09-307645>. IF 15,132. Cited by: WoS AD 156; WoS CC 149; Sc 163.
72. Bruno, B., **Gay, F.**, Boccadoro, M., & Palumbo, A. (2011). Management of myeloma: an Italian perspective. *Clinical Lymphoma, Myeloma & Leukemia*, 11 Suppl 1, S82–6. <https://doi.org/10.1016/j.clml.2011.03.026>. IF 2,308. Cited by: WoS AD 1; Sc 0.
73. **Gay, F.**, & Palumbo, A. (2011). Management of older patients with multiple myeloma. *Blood Reviews*, 25(2), 65–73. <https://doi.org/10.1016/j.blre.2010.10.003>. IF 6,600. Cited by: WoS AD 22; WoS CC 18; Sc 26.
74. Palumbo, A., & **Gay, F.** (2011). A new combination for advanced multiple myeloma. *The Lancet Oncology*, 12(3), 207–208. [https://doi.org/10.1016/S1470-2045\(11\)70036-5](https://doi.org/10.1016/S1470-2045(11)70036-5). IF 36,421. Cited by: WoS AD 0; WoS CC 0; Sc 0.
75. **Gay, F.**, Hayman, S. R., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., ... Rajkumar, S. V. (2010). Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. *Blood*, 115(7), 1343–1350. <https://doi.org/10.1182/blood-2009-08-239046>. IF 15,132. Cited by: WoS AD 76; WoS CC 73; Sc 95.
76. Palumbo, A., Larocca, A., Genuardi, M., Kotwica, K., **Gay, F.**, Rossi, D., ... GIMEMA. (2010). Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*, 95(7), 1144–1149. <https://doi.org/10.3324/haematol.2009.047913>. IF 9,090. Cited by: WoS AD 27; WoS CC 26; Sc 29.
77. **Gay, F.**, Rajkumar, S. V., Falco, P., Kumar, S., Dispenzieri, A., Petrucci, M. T., ... Palumbo, A. (2010). Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. *EUROPEAN JOURNAL OF HAEMATOLOGY*, 85(3), 200–208. <https://doi.org/10.1111/j.1600-0609.2010.01469.x>. IF 2,595. Cited by: WoS AD 7; WoS CC 5; Sc 8.
78. **Gay, F.**, Rajkumar, S. V., Coleman, M., Kumar, S., Mark, T., Dispenzieri, A., ... Niesvizky, R. (2010). Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. *AMERICAN JOURNAL OF HEMATOLOGY*, 85(9), 664–669. <https://doi.org/10.1002/ajh.21777>. IF 5,303. Cited by: WoS AD 37; WoS CC 36; Sc 40.
79. **Gay, F.**, & Palumbo, A. (2010). Multiple myeloma: management of adverse events. *Medical Oncology (Northwood, London, England)*, 27(3), 646–53. <https://doi.org/10.1007/s12032-009-9262-4>. IF 2,920. Cited by: WoS AD 13; WoS CC 13; Sc 17.
80. Palumbo, A., **Gay, F.**, Falco, P., Crippa, C., Montefusco, V., Patriarca, F., ... Boccadoro, M. (2010). Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. *JOURNAL OF CLINICAL ONCOLOGY*, 28(5), 800–807. <https://doi.org/10.1200/JCO.2009.22.7561>. IF 26,360. Cited by: WoS AD 128; WoS CC 126; Sc 142.
81. **Gay, F.**, & Palumbo, A. (2010). Management of disease- and treatment-related complications in patients with multiple myeloma. *MEDICAL ONCOLOGY*, 27(1), 43–52. <https://doi.org/10.1007/s12032-010-9542-z>. IF 2,920. Cited by: WoS AD 12; WoS CC 12; Sc 15.
82. Palumbo, A., & **Gay, F.** (2010). Towards a new standard of care for patients with myeloma? *The Lancet Oncology*, 11(1), 3–4. [https://doi.org/10.1016/S1470-2045\(09\)70313-4](https://doi.org/10.1016/S1470-2045(09)70313-4). IF 36,421. Cited by: WoS AD 1; WoS CC 1; Sc 2.

83. Corso, A., Zappasodi, P., Barbarano, L., Petrucci, M. T., Palumbo, A., Caravita, T., ..., **Gay, F.**, ... Lazzarino, M. (2009). Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. *Leukemia Research*, 33(9), e145–e149. <https://doi.org/10.1016/j.leukres.2009.03.015>. IF 2,319. Cited by: WoS AD 10; Sc 12.
84. Palumbo, A., Falco, P., Falcone, A., Benevolo, G., Canepa, L., **Gay, F.**, ... G, I. M. M. N. (2009). Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. *CLINICAL LYMPHOMA & MYELOMA*, 9(2), 145–150. <https://doi.org/10.3816/CLM.2009.n.035>. IF 1,130. Cited by: WoS AD 27; WoS CC 27; Sc 30.
85. Morabito, F., Gentile, M., Gay, F., Bringhen, S., Mazzone, C., Vigna, E., ..., **Gay, F.**, ... Palumbo, A. (2009). Insights into defibrotide: an updated review. *Expert Opinion on Biological Therapy*, 9(6), 763–772. <https://doi.org/10.1517/14712590903008507>. IF 3,974. Cited by: WoS AD 18; WoS CC 14; Sc 21.
86. Palumbo, A., & **Gay, F.** (2009). How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. *Hematology. American Society of Hematology. Education Program*, 2009(1), 566–77. <https://doi.org/10.1182/asheducation-2009.1.566>. IF 2,238. Cited by: WoS AD 26; Sc 35.
87. Musto, P., D’Auria, F., Pietrantuono, G., Baldini, L., Bringhen, S., Caravita, T., ..., **Gay, F.**, ... Palumbo, A. (2009). First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) Multiple Myeloma Working Party Perspective. *CURRENT DRUG TARGETS*, 10(10), 906–922. <https://doi.org/10.2174/138945009789577936>. IF 3,112. Cited by: WoS AD 4; WoS CC 3; Sc 6.
88. Palumbo, A., **Gay, F.**, Bringhen, S., Falcone, A., Pescosta, N., Callea, V., ... Boccadoro, M. (2008). Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, 19(6), 1160–5. <https://doi.org/10.1093/annonc/mdn018>. IF 13,930. Cited by: WoS AD 90; WoS CC 86; Sc 94.
89. Montefusco, V., **Gay, F.**, Spina, F., Miceli, R., Maniezzo, M., Ambrosini, M. T., ... Corradini, P. (2008). Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. *LEUKEMIA & LYMPHOMA*, 49(11), 2156–2162. <https://doi.org/10.1080/10428190802483778>. IF 2,644. Cited by: WoS AD 91; WoS CC 90; Sc 99.
90. Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A., Callea, V., ... Boccadoro, M. (2008). Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. *Blood*, 112(8), 3107–14. <https://doi.org/10.1182/blood-2008-04-149427>. IF 15,132. Cited by: WoS AD 259; WoS CC 251; Sc 293.
91. Palumbo, A., Magarotto, V., **Gay, F.**, Falco, P., Bringhen, S., & Boccadoro, M. (2008). Update on Recent Developments for Patients with Newly Diagnosed Multiple Myeloma. In Branicki, FJ and Adem, A and GhazalAswad, S and Torab, FC (Ed.), *RECENT ADVANCES IN CLINICAL ONCOLOGY* (Vol. 1138, pp. 19–21). <https://doi.org/10.1196/annals.1414.004>. IF 4,277. Cited by: WoS AD 2; WoS CC 2; Sc 2.
92. Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., **Gay, F.**, ... Harousseau, J.-L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. *Blood*, 111(8), 3968–3977. <https://doi.org/10.1182/blood-2007-10-117457>. IF 15,132. Cited by: WoS AD 192; WoS CC 184; Sc 210.
93. Palumbo, A., Falco, P., **Gay, F.**, Magarotto, V., Patriarca, F., Nozzoli, C., & Boccadoro, M. (2008). From cell biology to therapy: Lenalidomide in untreated multiple myeloma. *Haematologica Meeting Reports*, 2(5), 94–97.
94. Musto, P., Rossini, F., **Gay, F.**, Pitini, V., Guglielmelli, T., D’Arena, G., ... Cooperative, G. G. G. (2007). Efficacy and safety of bortezomib in patients with plasma cell leukemia. *CANCER*, 109(11), 2285–2290. <https://doi.org/10.1002/cncr.22700>. IF 6,537. Cited by: WoS AD 65; WoS CC 57; Sc 73.
95. Palumbo, A., Bringhen, S., Falco, P., Cavallo, F., Ambrosini, M. T., Avonto, I., ..., **Gay, F.**, ... Boccadoro, M. (2007). Time to first disease progression, but not beta 2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. *CANCER*, 110(4), 824–829. <https://doi.org/10.1002/cncr.22855>. IF 6,537. Cited by: WoS AD 9; WoS CC 9; Sc 11.
96. Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., ..., **Gay, F.**, ... Petrucci, M. T. (2007). Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA - Italian multiple myeloma network. *JOURNAL OF CLINICAL ONCOLOGY*, 25(28), 4459–4465. <https://doi.org/10.1200/JCO.2007.12.3463>. IF 26,360. Cited by: WoS AD 245; WoS CC 235; Sc 278.

97. Falco, P., Brighen, S., Avonto, I., **Gay, F.**, Morabito, F., Boccadoro, M., & Palumbo, A. (2007). Melphalan and its role in the management of patients with multiple myeloma. *EXPERT REVIEW OF ANTICANCER THERAPY*, 7(7), 945–957. <https://doi.org/10.1586/14737140.7.7.945>. IF 2,347. Cited by: WoS AD 19; WoS CC 19; Sc 18.
98. Palumbo, A., Avonto, I., Bruno, B., Falcone, A., Scalzulli, P. R., Ambrosini, M. T., ..., **Gay, F.**, ... Boccadoro, M. (2006). Intermediate-dose melphalan (100 mg/m<sup>2</sup>)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. *CLINICAL LYMPHOMA & MYELOMA*, 6(6), 475–477. <https://doi.org/10.3816/CLM.2006.n.028>. IF 1,130. Cited by: WoS AD 16; WoS CC !6; Sc 15.
99. Palumbo, A., Falco, P., Musto, P., Rossi, G., Giuliani, N., Morabito, F., ..., **Gay, F.**, ... Boccadoro, M. (2006). New treatment strategies for elderly myeloma patients. *Haematologica Reports*, 2(7), 113–114.

## BOOK CHAPTERS

1. **Gay, F.**, Oliva, S., & Palumbo, A. (2010). Treatment of Myeloma in Transplant-Ineligible Patients. In Kumar, S (Ed.), *Multiple Myeloma* (2nd ed., Vol. 1 l2, “Emerging Cancer therapeutics”, pp. 363–382). New York (US): Demos Medical Publishing. ISBN: 9781935281450. <https://doi.org/10.5003/2151-4194.1.2.363>
2. Palumbo, A., & **Gay, F.** (2009). Multiple Myeloma. In F. Cavalli, S. B. Kaye, H. H. Hansen, J. O. Armitage, & M. Piccart-Gebhart (Eds.), *Textbook of Medical Oncology* (4th ed., pp. 274–282). London (UK)–Boca Raton (FL-US): Informa Healthcare–Taylor & Francis. ISBN: 9780203092897.
3. Boccadoro, M., **Gay, F.**, Larocca, A., Magarotto, V., & Palumbo, A. (2008). Gammopatie monoclonali. In P. Corradini, R. Foa', M. Boccadoro, M. D. Cappellini, C. Carlo-Stella, M. Cattaneo, ... E. M. Pogliani (Eds.), *Manuale di Ematologia* (1st ed., pp. 183–194). Torino: Minerva Medica. ISBN: 9788877118165.

**Abbreviations.** IF, Impact Factor; WoS AD, Web of Science All Databases; WoS CC, Web of Science Core Collection; Sc, Scopus.

Turin, March 27, 2020

Dr. Francesca Maria Gay

## Attachment B. Oral and poster presentations

(First/last author or presenting author only)

### ORAL PRESENTATIONS

1. **Gay F.** Zaccaria GM, Offidani M, Vozella F, Becco P, ...Boccardo M. Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. Blood (2019) ASH Meeting Abstracts 134 (Supplement\_1): 605.
2. **Gay F.** C. Cerrato, M.T. Petrucci, R. Zambello, E. Rivolti, S. Ballanti, P.... M. Boccardo Carfilzomib, Lenalidomide, Dexamethasone (KRd) With or Without Transplantation in Newly Diagnosed Myeloma Patients: Subgroup Analysis in the FORTE Trial Haematologica, 104(s2), 1 [SIE 2019 47th Congress]. Retrieved from <http://www.haematologica.org/content/104/s2>
3. **Gay F.** Cerrato C., Rota Scalabrini D., Belotti A., Galli M., Zamagni E., ..., Boccardo M (2019). Carfilzomib Lenalidomide Dexamethasone (KRd) With or Without Transplantation in Newly Diagnosed Myeloma (FORTE Trial): Efficacy According to Risk Status. Abstract #S872, EHA 2019 24th Congress, selected for oral presentation (June 15, 2019).
4. **Gay, F.** Cerrato, C., Petrucci, M. T., Zambello, R., Gamberi, B., Ballanti, S., ... Boccardo, M. (2019). Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the forte trial. Abstract #8002 (ASCO 2019 Annual Meeting).
5. **Gay, F.** Cerrato, C., Scalabrini, D. R., Galli, M., Belotti, A., Zamagni, E., ... Boccardo, M. (2018). Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized FORTE Trial in Newly Diagnosed Multiple Myeloma (NDMM). Blood, 132(Suppl 1), Abstract #121 [ASH 2018 60th Meeting]. <https://doi.org/10.1182/BLOOD-2018-99-112093>
6. **Gay, F.** Rota Scalabrini, D., Belotti, A., Oliva, S., Rambaldi, A., Zamagni, E., ... Boccardo, M. (2018). UPDATED EFFICACY AND MRD DATA ACCORDING TO RISK-STATUS IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH CARFILZOMIB PLUS LENALIDOMIDE OR CYCLOPHOSPHAMIDE: RESULTS FROM THE FORTE TRIAL. HemaSphere, 2(s1), 6 [Abstract #s109, EHA 2018 23rd Congress].
7. **Gay, F.** Rota Scalabrini, D., Belotti, A., Offidani, M., Petrucci, M. T., Esma, F., ... Boccardo, M. (2017). Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM). JOURNAL OF CLINICAL ONCOLOGY, 35(15), Abstract #8003 [ASCO 2017 Annual Meeting]. [https://doi.org/10.1200/JCO.2017.35.15\\_suppl.8003](https://doi.org/10.1200/JCO.2017.35.15_suppl.8003)
8. **Gay, F.** Rota Scalabrini, D.; Belotti, A.; Offidani, M.; Tacchetti, P.; Petrucci, M. ... Boccardo, M. (2017). CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA. Haematologica, 102(s2), 143-144 [Abstract #S410, EHA 2017 22nd Congress].
9. **Gay, F.** Spadano, A., Cavo, M., Caravita, T., Canepa, L., Giuliani, N., ... Boccardo, M. (2017). INTERIM ANALYSIS OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE IN THE FORTE TRIAL. Haematologica, 102(s3), 1 [Abstract #B001, SIE 2017 46th Congress]. Retrieved from <http://www.haematologica.org/content/102/s3>

10. **Gay, F.**, Magarotto, V., Spencer, A., Di Raimondo, F., Pour, L., Scudla, V., ... Palumbo, A. (2016). UPFRONT OR RESCUE TRANSPLANT IN YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POOLED ANALYSIS OF 529 PATIENTS. *HAEMATOLOGICA*, 101(1), 3 [Abstract #S104, EHA 2016 21st Congress].
11. **Gay, F.**, D'Agostino, M., Hajek, R., Bringhen, S., Conticello, C., Gaidano, G., ... Boccadoro, M. (2016). Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. *Blood*, 128(22) [Abstract #995, ASH 2016 58th Annual Meeting].
12. **Gay, F.**, Genuardi, M., Hajek, R., Petrucci, M. T., Pour, L., Falcone, A. P., ... Palumbo, A. (2015). IMPROVED OVERALL SURVIVAL WITH AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A PHASE 3 TRIAL. *HAEMATOLOGICA*, 100(1), 1-2 [Abstract #S101, EHA 2015 20th Congress].
13. **Gay, F.**, Oliva, S., Hajek, R., Petrucci, M. T., Ria, R., di Toritto, T. C., ... Palumbo, A. (2015). A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS. *HAEMATOLOGICA*, 100(3), 30-31 [Abstract #C056, Italian Society of Hematology (SIE) 2015 45th Congress].
14. **Gay, F.**, Magarotto, V., Petrucci, M. T., Di Raimondo, F., Pour, L., Caravita, T., ... Palumbo, A. (2015). Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. *Blood*, 126(23): Abstract #392 [ASH 2015 57th Annual Meeting].
15. **Gay, F.**, Cavallo, F., Di Raimondo, F., Hardan, I., Nagler, A., Petrucci, M. T., ... Palumbo, A. (2014). IMPACT OF CONTINUOUS TREATMENT vs FIXED DURATION OF THERAPY IN NEWLY DIAGNOSED MYELOMA PATIENTS: PFS1, PFS2, OS ENDPOINTS. *HAEMATOLOGICA*, 99(1), 519 [Abstract #S1335, EHA 2014 19th Congress].
16. **Gay, F.**, Cerrato, C., Hajek, R., Di Raimondo, F., Caravita, T., Falcone, A. P., ... Palumbo, A. (2014). Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials. *Blood*, 124(21): Abstract #198 [ASH 2014 56th Annual Meeting].
17. Palumbo A., **Gay, F.** [pres.], Spencer, A., Di Raimondo, F., Zdenek, A., Larocca, A. ...Boccadoro, M (2014). Cyclophosphamide-Lenalidomide-Dexamethasone vs ASCT, followed by maintenance with Lenalidomide-Prednisone vs Lenalidomide alone in newly diagnosed MM patients: a phase 3 randomized EMN trial. Bone Marrow Transplantation. 2014, April [Abstract #PH-O132, 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, 2014].
18. **Gay, F.**, Hajek, R., Petrucci, M.T., Romano, A., Rocci, A., Fanin, R., ... Palumbo A (2013). Cyclophosphamide-Lenalidomide-Dexamethasone vs autologous transplant in newly diagnosed myeloma: a phase 3 trial. *Clinical Lymphoma, Myeloma & Leukemia*, 13(s1):s40 [Abstract #0-7, International Myeloma Workshop 2013 XIV Congress].
19. **Gay, F.**, Hajek, R., Petrucci M.T., Romano A., Rocci, A., Fanin, R. ... Palumbo A (2013). PROLONGED PROGRESSION-FREE SURVIVAL WITH AUTOLOGOUS TRANSPLANTATION COMPARED WITH CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE IN NEWLY DIAGNOSED MYELOMA: A PHASE 3 TRIAL. *Haematologica*, 98(s3):75 [Abstract #P043, Italian Society of Hematology (SIE) National Congress 2013]
20. **Gay, F.**, Larocca, A., Mateos, M., Oliva, S., Offidani, M., Ria, R. ... Palumbo, A (2012). COMPLETE RESPONSE IS A STRONGER PREDICTOR OF SURVIVAL THAN CYTOGENETIC PROFILE AND INTERNATIONAL STAGING SYSTEM STAGE IN ELDERLY MYELOMA PATIENTS TREATED WITH BORTEZOMIB: ANALYSIS OF 771 PATIENTS. *Haematologica*, 97(s1):242 [Abstract #591, EHA 2012 17th Congress].
21. **Gay, F.**, Oliva, S., Ferrari, S., Montefusco, V., Patriarca, F., Liberati A. M. Palumbo, A. (2011). POST-TRANSPLANT LENALIDOMIDE CONSOLIDATION - MAINTENANCE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: UPDATED RESULTS OF A PHASE II TRIAL. *Haematologica*, 96(s3):8 [Abstract# C007, Italian Society of Hematology (SIE) 43rd Congress].
22. **Gay, F.**, Larocca, A., Petrucci, M. T., Musto, P., Liberati, A. M., Callea, V., ... Palumbo, A. (2010). ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN ELDERLY MYELOMA PATIENTS TREATED WITH

- MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF THE GISMM2001, RV-MM-PI-026 AND GIMEMA-MM-03-05 MULTICENTER ITALIAN TRIALS. *Haematologica*, 95(s3), S100 [Abstract #P075, Italian Society of Experimental Hematology XI Congress].
23. **Gay, F.**, Larocca, A., Petrucci, M. T., Musto, P., Liberati, A. M., Callea, V., ... Palumbo, A. (2010). ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS. *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*, 95(2), 236 [Abstract #0570, EHA 2010 15th Congress].
  24. Palumbo, A., Cavo, M., Bringhen, S., Cavalli, M., Patriarca, F., Rossi, D., ... Boccadoro, M. (2009). A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens. *Blood*, 114(22), Abstract #492 [ASH 2009 51st Meeting; **presented by Dr. F. Gay**].
  25. **Gay, F.**, Bringhen, S., Crippa, C., Montefusco, V., Patriarca, F., Liberati, A. M., ... Palumbo, A. (2009). BORTEZOMIB-DOXORUBICIN-DEXAMETHASONE INDUCTION BEFORE AUTOLOGOUS TRANSPLANTATION, FOLLOWED BY LENALIDOMIDE CONSOLIDATION-MAINTENANCE IN UNTREATED MYELOMA PATIENTS. *Haematologica*, 94(s4), 45-46 [Abstract #C093, Italian Society of Hematology, 42nd Congress].
  26. Palumbo, A., **Gay, F.**, Falcone, A., Pescosta, N., Callea, V., Caravita, T., ... Boccadoro, M. (2007). ASSOCIATION OF BORTEZOMIB, DOXORUBICIN AND DEXAMETHASONE (PAD) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS. *Haematologica*, 92(s3), 31-32 [Abstract #C-067, Italian Society of Hematology, 41st Meeting, presented by F. Gay].

## POSTER PRESENTATIONS

1. Oliva S, Genuardi E, Belotti A, Frascione P, Galli M, Capra A, .... **Gay F** Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients *Blood* (ASH meeting abstract 2019) 134 (Supplement\_1): 4322.
2. Zaccaria GM, Capra A, Petrucci MT, Offidani M, Montefusco V, DI Raimondo F, .... **Gay F** Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset *Blood* (ASH Annual meeting 2019) 134 (Supplement\_1): 2130.
3. **Gay, F.**, Dimopoulos, MA, Schjesvold, FH, Beksac, M, Hajek, R, Weisel, KC, Rajkumar, SV, MAINTENANCE THERAPY WITH THE ORAL PROTEASOME INHIBITOR (PI) IXAZOMIB SIGNIFICANTLY PROLONGS PROGRESSION-FREE SURVIVAL (PFS) POST-TRANSPLANT IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): THE PHASE 3 TOURMALINE-MM3 TRIAL, presented at the Controversies in Multiple Myeloma Meeting held in Paris, May 16-18 2019.
4. **Gay, F.**, De Paoli, L., Larocca, A., Musolino, C., Genuardi, M., Montefusco, V., ... Boccadoro, M. (2018). LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS. *HemaSphere*, 2(s1), 590 [Abstract #PS1299, EHA 2018 23rd Congress].
5. **Gay, F.**, Offidani, M., Günther, A., Salvini, M., Engelhardt, M., Poenisch, W., ... Gramatzki, M. (2018). CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG). *HemaSphere*, 2(s1), 230 [abstract #PF561, EHA 2018 23rd Congress].
6. **Gay, F.**, Foà, R., Musto, P., Cerrato, C., Gamberi, B., Zamagni, E., ... Boccadoro, M. (2018). Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial). *Journal of Clinical Oncology*, 36(15\_suppl), Abstract #8009 [ASCO 2018 Annual Meeting]. [https://doi.org/10.1200/JCO.2018.36.15\\_suppl.8009](https://doi.org/10.1200/JCO.2018.36.15_suppl.8009)
7. **Gay, F.**, Rota Scalabrini, D., Belotti, A., Galli, M., Zamagni, E., Offidani, M., ... Boccadoro, M. (2017). A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone

Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients. *Blood*, 130(Suppl 1), Abstract #4541 [ASH 2017 59th Meeting]. Retrieved from [http://www.bloodjournal.org/content/130/Suppl\\_1/4541?sso-checked=true](http://www.bloodjournal.org/content/130/Suppl_1/4541?sso-checked=true)

8. **Gay, F.**, Günther, A., Offidani, M., Engelhardt, M., Schub, N., Gentili, S. (2017). A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma. *Clinical Lymphoma, Myeloma & Leukemia*, 17(1):e125-e126 [Abstract #PS-225, International Myeloma Workshop (IMW) 2017 XVI Congress].
9. **Gay, F.**, Bringhen, S., Offidani, M., Liberati, A., Cellini, C., Magarotto, V., ... Palumbo, A. (2013). EFFICACY AND SAFETY OF 3 LENALIDOMIDE-BASED COMBINATIONS IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS FROM THE PHASE 3 COMMUNITY BASED EMN01 TRIAL. *HAEMATOLOGICA*, 98(1), 95-96 [Abstract #P221, EHA 2013 18th Meeting].
10. **Gay, F.**, Cavallo, F., Caravita, T., Cavalli, M., Nagler, A., Montefusco, V., ... Palumbo, A. (2013). Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. *Blood*, 122(21), Abstract #2089 [ASH 2013 55th Annual Meeting].
11. **Gay, F.**, Hayman, S., Buadi, F., Detweiler-Short, K., Lacy, M., Kumar, S., ... Rajkumar, V. (2010). SAFETY AND EFFICACY OF LENALIDOMIDE PLUS DEXAMETHASONE IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS 70 YEARS OF AGE AND OLDER. *Haematologica*, 95(2), 153 [Abstract #0379, EHA 2010 15th Congress].
12. **Gay, F.**, Larocca, A., Wijermans, P. W., Bringhen, S., Guglielmelli, T., Schaafsma, M. R., ... Palumbo, A. (2010). Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients. *Blood*, 116(21): 812 [Abstract #1949, ASH 2010 52th Annual Meeting].
13. **Gay, F.**, Bringhen, S., Genuardi, M., Rossi, D., Ria, R., Romano, A., ... Palumbo, A. (2009). The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy. *Blood*, 114(22), 1495-1496 [Abstract #3887, ASH 2009 51th Annual Meeting].
14. **Gay, F.**, Falco, P., Crippa, C., Liberati, M., Patriarca, F., Cangialosi, C., ... Palumbo, A. (2009). Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients. *Blood*, 114(22), 1328 [Abstract #3419, ASH 2009 51th Annual Meeting].
15. **Gay, F.**, Hayman, S., Lacy, M. Q., Buadi, F., Gertz, M. A., Kumar, S., ... Rajkumar, S. V. (2009). Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma. *Blood*, 114(22), 1494-1495 [Abstract #3884, ASH 2009 51th Annual Meeting].
16. **Gay, F.**, Rajkumar, S. V., Falco, P., Kumar, S., Dispenzieri, A., Gertz, M., ... Palumbo, A. (2009). Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. *Blood*, 114(22), 1123 [Abstract #2877, ASH 2009 51th Annual Meeting].
17. **Gay, F.**, Rajkumar, S. V., Jayabalan, D. S., Kumar, S., Mark, T., Dispenzieri, A., ... Niesvizky, R. (2009). Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma. *Blood*, 114(22), 1119-1120 [Abstract #2868, ASH 2009 51th Annual Meeting].

Turin, March 27, 2020

Dr. Francesca Maria Gay

## Attachment C. National and international meetings

### CHAIR

1. 61st American Society of Hematology (ASH) Annual Meeting, Orlando, FL, USA 7 - 10 December 2019;
2. XVII International Myeloma Workshop (IMW), Boston, USA, 12-15 September 2019.
3. European Hematology Association (EHA) 24<sup>th</sup> Congress, Amsterdam, 13-16 June 2019.
4. 2nd How to Diagnose and Treat Multiple Myeloma, European School of Hematology (ESH), Berlin, 5-7 April 2019.
5. Korean Society of Hematology (KSH) International Conference & the 6<sup>th</sup> Annual Meeting, Seoul 14-16 March 2019.
6. XVI International Myeloma Workshop (IMW) New Delhi, India, dal 1 al 4 March 2017.
7. 21st Congress of the European Hematology Association (EHA), Copenhagen, 9-12 June 2016.
8. 18th Congress of the European Hematology Association (EHA), Stockholm, Svezia, dal 13 al 16 June 2013;
9. 54st American Society of Hematology (ASH) Annual Meeting, Atlanta, GE, USA dal 8 al 11 December 2012;
10. 53st American Society of Hematology (ASH) Annual Meeting, San Diego, CA, USA dal 10 al 13 December 2011.

### INVITED SPEAKER – SELECTED INTERNATIONAL AND NATIONAL MEETINGS

1. EHA-ISHBT Hematology Tutorial on Hematological Disorders, Chandigar, India, 27-28/02/2020  
*Multiple myeloma (Webex due to travel limitation for COVID-19 disease travel limitation)*
2. European Multiple Myeloma Academy (EMMA), Vienna, Austria, 25/1/2020.  
*Treatment of high-risk myeloma: estramedullary disease and plasmacell leukemia*
3. ASH 2019 61st Meeting, Friday Scientific Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma  
*Adaption of Next Generation Sequencing, Next Generation Flow Cytometry, CyTOF and New Approaches to Bone and Soft Tissue Imaging of PCD: Next Generation Sequencing Comparison to Next Generation Flow Cytometry*
4. HEMO, Brazilian Congress of Hematology, 6-9/11/2019, Rio de Janeiro, Brasil,  
*How to define and manage high-risk myeloma patients*  
*Amgen symposium Is it worthless to keep prescribing ASCT for myeloma?*
5. Speaker at 2nd CMWP Scientific & Educational Meeting, Istanbul, Turkey, 19/10/19.  
*Multiple Myeloma, Treatment of transplant Ineligible patients*
6. Speaker at Hematologic Malignancies, Rimini, Italy, 18 October 2019; *Multiple Myeloma, Risk factors and Criteria for treatment*
7. Speaker at 47° Congresso Nazionale SIE (Società Italiana di Ematologia), Luch Meeting, ROMA, Italy, da 7 al 8 October 2019; *Lo scenario terapeutico del Mieloma Multiplo di oggi e del futuro, L'importanza del meccanismo d'azione del carfilzomib per il beneficio clinico nel mieloma multiplo*
8. 20th European Multiple Myeloma Academy (EMMA) Congress, Madrid, Spain, 04-05/10/2019.  
*Workshop: Optimize diagnosis and monitoring in myeloma*
9. XVII International Myeloma Workshop (IMW), Boston, USA, 12-15 September 2019.  
*Should we use MRD for drug development and approval?*  
*Primary Plasma cell leukemia*



10. Highlights from past (24<sup>th</sup>) EHA, HOPE, Kolkata, India, 23-25 August 2019.  
*Optimal sequencing in relapsed/refractory myeloma*
11. European Hematology Association (EHA) 24th Congress, 14th June 2019.  
*Meet the Expert: Optimal sequencing in relapsed/refractory myeloma*
12. Controversies in Multiple Myeloma (COMy), Paris, France, 16-18/4/2018.  
(1) *Management of Special Situations: Plasma-Cell Leukemia;*  
(2) *Amgen Satellite Symposium Evolving therapeutic possibilities in multiple myeloma*
13. 2nd European School of Hematology (ESH) Meeting on How to Diagnose and Monitor Multiple Myeloma, Berlin, 5-7/04/2019.  
(1) *From Studies to Reality: A Transplant-Eligible Patient with a Non-Aggressive Relapse 24 Months after Autologous Stem-Cell Transplant Followed by Lenalidomide Maintenance.*  
(2) *Meet the expert "Stem Cell Transplantation"*
14. British Society of Hematology Annual Meeting, UK Myeloma Forum, Glasgow, United Kingdom, 1/04/2019.  
*Host and Tumor Biomarkers: A Route to Ultra-Stratification.*
15. Korean Society of Hematology International Conference & 60th Annual Meeting, European Hematology Association-Korean Society of Hematology Joint Symposium, Seoul, South Korea March 15 2019.  
(1) *Multiple Myeloma. Experimental Therapy except Monoclonal Antibodies;*  
(2) *Multiple Myeloma. Monoclonal Antibodies in the Treatment of Multiple Myeloma.*
16. European Multiple Myeloma Academy (EMMA), Vienna, Austria, 31/1/2019.  
*Diagnostic Workup in Patients with Paraproteinemia.*
17. 1° Workshop di Ematologia Neoplastica, Palermo, Italy, 25/1/2019  
*Mieloma multiplo recidivato e refrattario.*
18. International Congress "Multiple Myeloma and Related Malignancies," 4th edition, Bari, 9/11/2018.  
*Benefit And Toxicity For The Choice Of Therapy.*
19. HEMO, Brazilian Congress of Hematology, 1/11/2018, San Paolo, Brasil, Janssen symposium "Redefining the History of Multiple Myeloma".  
*Optimizing Treatment in Relapsed/Refractory Multiple Myeloma Patients.*
20. International Myeloma Society (IMS) Educational workshop, 26/10/2018, Athens, Greece.  
*Why Should We Use Maintenance?*
21. 17th Annual meeting of the Italian and Brazilian Association of Hematology (AIBE), Torino, Italy, 22/10/2018.  
*Myeloma Therapy and Clinical Ongoing Research in Italy.*
22. 15° Italian Society of Experimental Hematology Association (SIES) Congress, Rimini, Italy, 19/10/2018, Celgene Symposium "L'immunomodulazione continua nel trattamento del mieloma multiplo".  
*La terapia in recidiva.*
23. European School of Hematology (ESH) 4th International Conference on Multiple Myeloma, Mandelieu, France, 5-7/10/2018, Janssen Satellite Symposium.  
*How I treat Myeloma Patients.*
24. Joint Symposium Italian Hemostasis and Thrombosis Society (SISST)-Italian Society of Hematology (SIE), Alessandria, Italy, 28/9/2018.  
*Mieloma multiplo: quali novità nel trattamento.*
25. Norwegian Society of Hematology Autumn's Meeting, Oslo, Norway 25-26/9/2018.  
*Multiple Myeloma: Tandem Transplant and Maintenance.*

26. Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) Educational Congress, “Il trapianto allogenico nei linfomi e nel mieloma multiplo”, Udine, Italy, 20-21/09/2018.  
*Multiple Myeloma: Current Indication for SCT at Diagnosis and at Relapse. The Trialist Perspective.*
27. 18th European Multiple Myeloma Academy (EMMA) Congress, Madrid, Spain, 14-15/09/2018.  
*Workshop: Autodiagnose and Monitor Myeloma in 2018 (From Proteins to Molecular; From X-Ray to PET. Do We Need 24-Hour Urine?)*
28. 23rd Congress of EHA (European Hematology Association), Stockholm, Sweden, 14-16 June 2018 (Janssen symposium).  
*Patients' and Physicians' Perspectives in Recent Advances in the Treatment for Multiple Myeloma.*
29. Controversies in Multiple Myeloma (COMy), Paris, France, 3-5/4/2018.  
*Management of Special Situations: Plasma-Cell Leukemia.*
30. 1st Meeting of the European-Myeloma-Network (EMN), Torino (Italy), 19-21/04/2018.  
(1) *When to Use Novel Proteasome Inhibitors and Immunomodulatory Drugs. Haematologica 2018, 103(1), 7.*  
(2) *Janssen Symposium. Practical Management Considerations on the New Therapeutic Options in Relapsed and Refractory Multiple Myeloma.*  
(3) *Celgene Symposium. Practical Implications of IMiD Compound Therapy.*
31. International Myeloma Society (IMS) Educational workshop, 29-30/09/2017, Prague, Czech Republic.  
*When Should We Use Maintenance?*
32. Speaker at 46° Congresso Nazionale SIE (Società Italiana di Ematologia), Luch Meeting, ROMA, Italy, da 15 al 17 October 2017; *Mieloma Multiplo, riflessioni su uno scenario complesso, dalla tattica alla strategia*
33. European Cancer Congress [ECCO] 2017, Amsterdam, 29/01/2017.  
*What's New In Multiple Myeloma?*
34. Lymphoma and Myeloma 2016 Meeting, New York, 13/10/2016.  
*Immunologic Approaches: CAR T, Checkpoint Inhibitors, Monoclonal Antibodies.*
35. Best of EHA, Mumbai 22-24/07/2016.  
(1) *New Definition of Myeloma, Newer Staging System & Role of MRD Detection;*  
(2) *Understanding The Heterogeneity of Myeloma - A Key to Success;*  
(3) *Immuno-Oncology, Newer MiBs And MaBs in the Treatment of Myeloma.*
25. International Myeloma Workshop (IMW) 2015 XV Congress, Rome, 23-26/09/2015).  
*How I Use Supportive Care And Palliation.*
26. Regional Congress of the Italian Society of Hematology (SIE). “Focus sul mieloma multiplo”, Cagliari (Italy), 30-31-05-2014.  
*Il trattamento del mieloma su stratificazione di rischio: è oggi possibile?*

## Other meetings/patient seminars

\*When “speaker” is not specified, it is meant as “participant”.

### International meetings

1. Lectures with the Israelian Myeloma Working group, Tel AVIV 22-24 January 2020
2. Speaker (abstract selected for oral presentation) at 61th ASH (America Society of Hematology) Annual Meeting, Orlando, FL, USA dal 7 al 10 December 2019;
3. Speaker at 18<sup>th</sup> annual meeting of the AIBE association 9 November 2019, Rio de Janeiro, Brasile;

4. Speaker at 11h Trialist Forum. European Myeloma Network, Baveno (Verbania), Italy, dal 29 al 30 September 2019;
5. Speaker (abstract selected for oral presentation) at European Hematology Association (EHA) 24<sup>th</sup> Congress, Amsterdam, 13-16 June 2019.
6. Speaker at Hematology Debate 2019, Madrid, Spain, February 7 2019.
7. Speaker at 2nd Global Summit on Hematologic Malignancies, Lisbona, Portugal, February 14-16 2019.
8. Speaker (abstract selected for oral presentation) at 60th ASH (America Society of Hematology) Annual Meeting, San Diego, CA, USA dal 1 al 4 December 2018;
9. Speaker at LACAN Hematology Summit, Buenos Aires, Argentina, 15-17 November 2018;
10. Speaker at 19th Myeloma Workshop Starnberger See, Munich, Germania, 10 November 2018;
11. Speaker at HEMATO EXPERTS – How I Treat MM and WM, 31 October 2018, San Paolo, Brasile;
12. Speaker at 17<sup>th</sup> annual meeting of the AIBE association 23 October 2018, Torino, Italy;
13. Speaker at Updates in Hematologic Malignancies: How to Manage CLL, MCL and MM, Milano, Italy, 4 October 2018;
14. Speaker at 10h Trialist Forum. European Myeloma Network, Baveno (Verbania), Italy, dal 23 al 24 September 2018;
15. Speaker (abstract selected for oral presentation) at 22st Congress of EHA (European Hematology Association), Stoccolma, Svezia, dal 14 al 17 June 2018;
16. IMWG (international Myeloma Working group) Meeting, Stoccolma, Svezia, dal 12 al 13 June 2018;
17. Speaker (abstract selected for oral presentation) at 2018 ASCO (American Society of Hematology) Annual Meeting, Chicago, USA, dal 1 al 5 June 2018;
18. Speaker at MyKE (Myeloma Knowledge Exchange) 2018, Vienna, Austria, 27-28 April 2018;
19. Speaker at European Cooperative Groop Meeting, Parigi, 12-13 April 2018;
20. Speaker at 9th Investigator Research Meeting, Francoforte, Germania, dal 23 March al 24 March 2018;
21. Riunione EMN-EMN-Italy, Amsterdam, Olanda, 22 March 2018;
22. Riunione EMN-EMN-Italy, Amsterdam, Olanda, 15 March 2018;
23. Speaker at 1st Global Summit on Hematologic Malignancies, Madrid, Spagna, 16-17 February 2018;
24. Speaker at Hematology Debate 2019, Roma, Italy, 7-8 February 2018;
25. 59st ASH (America Society of Hematology) Annual Meeting, Atlanta, GA, USA dal 9 al 12 December 2017;
26. Speaker at 19th Myeloma Workshop Starnberger See, Munich, Germania, 11 November 2017;
27. Speaker at Multiple myeloma 2017 keeping track in a multifaceted landscape of treatment strategies, Freiburg, Germania, 25 October 2017;
28. Speaker at 9th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italy, dal 24 al 25 September 2017;
29. Speaker (abstract selected for oral presentation) at 22st Congress of EHA (European Hematology Association), Madrid, Spagna, dal 22 al 25 June 2017;
30. IMWG (international Myeloma Working group) Meeting, Madrid, Spagna, dal 20 al 21 June 2017;
31. Speaker (abstract selected for oral presentation) at 2017 ASCO (American Society of Hematology) Annual Meeting, Chicago, USA, dal 2 al 6 June 2017;
32. 8th Investigator Research Meeting, Saronno, Italy, dal 31 March al 1 April 2017;
33. XVI International Myeloma Workshop (IMW) New Delhi, India, dal 1 al 4 March 2017.
34. Speaker at Opinioni a confronto in Oncologia: mieloma multiplo, Bellinzona, Svizzera, 9 February 2017;
35. Speaker at (abstract selected for oral presentation) 58st ASH (America Society of Hematology) Annual Meeting, San Diego, CA, USA dal 3 al 6 December 2016;
36. Speaker at 8th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italy, dal 24 al 25 September 2016;
37. Speaker at 9th Myeloma Workshop Starnberger See, Munich, Germania, dal 16 al 17 September 2016;
38. Speaker (abstract selected for oral presentation) at 21st Congress of EHA (European Hematology Association), Copenhagen, Danimarca, dal 9 al 12 June 2016;
39. ASCO Annual Meeting, Chicago, IL, USA, dal 3 al 7 June 2016;
40. Monoclonal Antibodies in multiple myeloma: an in-depht educational update, Alcada de Henares, Spagna, dal 12 al 13 May 2016;
41. Speaker at Myeloma Knowledge Exchange, Berlino, Germania, dal 8 al 9 May 2016;
42. 7th Investigator Research Meeting, Vienna, Austria, dal 4 al 5 March 2016;
43. Speaker (abstract selected for oral presentation) at 57st ASH (America Society of Hematology) Annual Meeting, Orlando, FL, USA dal 5 al 8 December 2015;
44. Speaker at 8th Myeloma Workshop Starnberger See, Munich, Germania, dal 19 al 20 November 2015;

45. Speaker (abstract selected for oral presentation) at 20th Congress of EHA (European Hematology Association), Vienna, Austria, dal 11 al 14 June 2015;
46. Speaker at (abstract selected for oral presentation) 56st ASH (America Society of Hematology) Annual Meeting, San Francisco, CA, USA dal 6 al 9 December 2014;
47. Speaker at 7th Myeloma Workshop Starnberger See, Munich, Germania, dal 19 al 20 September 2014;
48. Speaker at 7th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italy, dal 14 al 15 September 2014;
49. Speaker (abstract selected for oral presentation) at 19th Congress of EHA (European Hematology Association), Milano, Italy, dal 12 al 15 June 2014;
50. Speaker (abstract selected for oral presentation) at 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milano, Italy, dal 30 March al 2 April 2014;
51. Speaker (abstract selected for oral presentation) at 55st ASH (America Society of Hematology) Annual Meeting, New Orleans, LA, USA dal 7 al 10 December 2013;
52. Multiple Myeloma and Related Malignancies 2nd edition, Bari dal 7 al 9 November 2013;
53. Speaker at 6th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italy, dal 15 al 16 September 2013;
54. Speaker (abstract selected for oral presentation) at XIV International Myeloma Workshop Kyoto, Japan, dal 3 al 7 April 2013;
55. Speaker (abstract selected for oral presentation) at 17th Congress of EHA (European Hematology Association), Amsterdam, The Netherlands, dal 14 al 17 June 2012;
56. Speaker at 5th Trialist Forum. European Myeloma Network, Baveno (Verbania), dal 13 al 14 May 2012;
57. Speaker at What to do for Refractory Hematologic Malignancies: comparing Italian and German Experiences, Bolzano, Italy, dal 2 al 3 November 2011;
58. 16th Congress of EHA (European Hematology Association), London, United Kingdom, dal 9 al 12 June 2011;
59. Investigator Meeting CC5013MM015, Warsaw, Poland, 18 May 2011;
60. Speaker at 4th Trialist Forum. European Myeloma Network, Baveno (Verbania), Italy, dal 15 al 16 May 2011;
61. 13th International Myeloma Workshop Paris, Francia, dal 3 al 6 May 2011;
62. Advanced Course on Multiple Myeloma, John Hopkins University, Baltimore, MN, USA, dal 12 al 14 October 2010;
63. Speaker (abstract selected for oral presentation) at 15th Congress of EHA (European Hematology Association), Barcellona, Spagna, dal 10 al 13 June 2010;
64. Speaker at 3rd Trialist Forum: European Myeloma Network, Baveno, Italy, 16-17 May 2010;
65. Speaker (abstract selected for oral presentation) at 51st ASH (America Society of Hematology) Annual Meeting, New Orleans, LA, USA dal 5 al 8 December 2009;
66. XII International Myeloma Workshop Washington, DC, USA, dal 26 February 2009 al 1 March 2009;
67. 50th ASH (American Society of Hematology) Annual Meeting, San Francisco, CA, USA, dal 6 al 9 December 2008;
68. 34th Annual Meeting of the European Group for Blood and Marrow Transplantation, Firenze, Italy, dal 30 March al 2 April 2008, with final examination (4 credits);
69. European Trialist Forum: Advances in Leukemia, Lymphoma and Myeloma, Torino, Italy, 6-7 February 2008;
70. 49th American Society of Hematology Annual Meeting, Atlanta, GE, USA, dal 8 al 11 December 2007;

### National meetings

1. Speaker at "Post IMW" Bologna, Italy, 19/11/19.
2. Speaker at "Master di II Livello in diagnosi e terapia dei pazienti con linfoma e Malattie linfoproliferative" Trieste, Italy, 24/10/19.
3. Speaker at "Forum in Ematologia verso il 2020" Bari, Italy, 21/10/19.
4. Speaker (abstract selected for oral presentation) at 47° Congresso Nazionale SIE (Società Italiana di Ematologia), ROMA, Italy, da 7 al 8 October 2019;
5. Speaker at Hema FORUM, "Per costruire insieme l'ematologia di domani", Milano, Italy, April 5 2019.
6. Board for the treatment of Young Myeloma Patients; European Myeloma Network (EMN), Bologna, Italy, February 14 2019.
7. Speaker at Immunotalk Mieloma Multiplo, Milano, Italy, 5 February 2019 with final examination (ECM);
8. Speaker at Mieloma 3.0 risultati ottenuti e obiettivi futuri, Milano, Italy, 21-22 January 2019 e 3-4 April 2019, ECM.
9. Investigator meeting EMN18, Roma, Italy, 15-16 January 2019;
10. Tavola Rotonda PRIMO, Torino 9 October 2018;
11. Corso ALS, Torino, Italy, 3-4 October 2018 with final examination (ECM);
12. Immediate Life Support, Torino, Italy, 11 May 2018, with final examination (ECM);
13. Riunione EMN-Italy, Bologna, Italy, 12 February 2018;

14. Speaker at Convegno “il paziente ematologico complicato” Brescia, Italy, 1 December 2017;
15. Speaker at Convegno “le terapia del mieloma multiplo: uno scenario in continua evoluzione”, Bologna, Italy, 27 November 2017;
16. Convegno “Il mieloma multiplo, un anno di cambiamenti”, Torino, Italy, il 16 November 2017;
17. Speaker at Presentazione nell’ambito del programma “Hematology University 2017”, Milano, Italy, il 10 November 2017;
18. Speaker at Convegno “La quadreria dell’Ematologia”, Pesaro, Italy, il 7 November 2017;
19. Speaker (abstract selected for oral presentation) at 46° Congresso Nazionale SIE (Società Italiana di Ematologia), ROMA, Italy, da 15 al 17 October 2017;
20. Speaker at Conferenza “Il Mieloma: recenti acquisizioni”, Torino, Italy, il 16 June 2017;
21. Speaker at A Closer look at immuno-oncology in multiple myeloma, Napoli, Italy, dal 26 al 27 May 2017;
22. Basil Life Support (BLS), Torino, Italy, 5 April 2017; with final examination (ECM);
23. Speaker at Progressi in Ematologia, I giovani come protagonisti, Napoli, Italy, dal 24 al 25 March 2017;
24. Speaker at Meeting Mieloma, Torino, Italy, 13 January 2017;
25. Speaker at Sky Forum: nuovi scenari terapeutici, Pollenzo, Italy dal 24 al 25 November 2016;
26. La nuova era degli anticorpi monoclonali nel trattamento del mieloma multiplo, Napoli, Italy, 21 November 2016;
27. Speaker at Under 40 in Hematology 2016, Villafranca di Verona, Italy, 17 November 2016;
28. Speaker at 6th International Palermo Conference on Innovative therapies for lymphoid malignancies, Palermo, Italy, dal 10 al 12 November 2017;
29. Speaker at Nuovo cinema ematologia: the directors cut, Pesaro, 8 November 2016, without final examination (1 ECM credit);
30. Speaker at Giornate ematologiche vicentine, VII Edizione, 11 October 2016;
31. Corso teorico pratico nella gestione ottimale del paziente anziano affetto da neoplasie ematologiche, Torino, dal 3 al 4 October 2016; with final examination (19 ECM credits);
32. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italy, dal 28 al 30 September 2016;
33. Speaker at Mieloma Multiplo scenari in evoluzione, Torino, Italy, 20 September 2016;
34. Terapia antifungina: confronto con gli esperti. Necrotizing Enterocolitis (NEC): approccio diagnostico e terapeutico, Torino, il 25 May 2016; with final examination (3,5 credits);
35. Speaker at FORUM M 2016, Torino, Italy, dal 13 al 14 April;
36. Speaker at Under 40 in Hematology, Simposio “Gli anticorpi monoclonali nel mieloma multiplo: l’inizio di una nuova era, Villafranca di Verona, Italy, 13 November 2015;
37. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italy, dal 19 al 21 October 2015;
38. Speaker (abstract selected for oral presentation) at 45° Congresso Nazionale SIE (Società Italiana di Ematologia), Firenze, Italy, da 4 al 5 October 2015;
39. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italy, dal 27 al 28 September 2015;
40. Speaker at XXIII Edizione corso Cefar Le Proteine: dal laboratorio alla Clinica, Bologna, Italy, 5 May 2015;
41. Elementi di statistica per l’impostazione di un protocollo di studio in onco-ematologia, Roma, Italy, 17 December 2014;
42. Speaker at HemaExcellence: la comunicazione efficace in ematologia, Torino, Italy, dal 20 al 21 November 2014;
43. Speaker at Under 40 in Hematology 2014, Roma, Italy, dal 13 al 14 November 2014;
44. Speaker at Innovazione nella gestione del Mieloma Multiplo, Milano, Italy, 6 November 2014;
45. Speaker at Novità nei Linfomi Aggressivi e nella Leucemia Linfoblastica Acuta, Torino, Italy, 27 October 2014;
46. Speaker at Appropriatazza di utilizzo di Bendamustina nel mieloma multiplo, Torino, Italy, 24 October 2014;
47. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italy, dal 6 al 8 October 2014;
48. Speaker at Effective Cancer Therapy through immunomodulation, Milano, Italy, dal 29 al 30 September 2014;
49. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italy, il 17 June 2014;
50. Investigator meeting for protocol IST 1097-03, Milano, Italy, 15 June 2014;
51. Speaker at Progetto MOVE (mozobil value evidence), Torino, Italy, 17 January 2014;
52. Speaker at Under 40 in Hematology 2013, Torino, Italy, dal 14 al 15 November 2013;
53. Speaker at Rapid Fire in Hematology, Esperienze Cliniche a confronto sul mieloma multiplo, Milano, Italy, 26 June 2013;
54. Speaker at Highlights from IMW 2013, Bologna, Italy, 28 May 2013;
55. Advance Cardiovascular Life Support (ACLS) Corso Provider, Torino, Italy, 9 e 10 May 2013;

56. Speaker at Grandangolo in Ematologia, selezione ragionata dei più recenti dati scientifici, III edizione, Milano, Italy, dal 19 al 20 November 2012;
57. Speaker at Under 40 in Hematology 2013, Napoli, Italy, dal 15 al 16 November 2012;
58. Speaker at Attuali conoscenze e prospettive future dell'approccio sequenziale, con mantenimento e/o consolidamento postinduzione, alla terapia delle neoplasie ematologiche, Bolzano, Italy, 30 October 2012;
59. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italy, dal 18 al 19 September 2012;
60. Il Processo di accreditamento all'eccellenza Jacie e la normativa ISO 9001:2008: il trapianto autologo e lo scongelamento delle sacche criopreservate, Torino, Italy, dal 12 al 13 September 2012, with final examination;
61. Speaker at La gestione del paziente anziano nelle neoplasie ematologiche, Milano, Italy, 28 June 2012;
62. Speaker at Rapid Fire in Hematology: esperienze cliniche a confronto sul mieloma multiplo, Milano, Italy, 29 May 2012;
63. Progetto Risk Management e l'errore in terapia, corso FAD Regione Piemonte, Torino, Italy, 26 February 2012 (ECM);
64. Speaker at Grandangolo in Ematologia, selezione ragionata dei più recenti dati scientifici, II edizione, Milano, Italy, dal 14 al 15 November 2011;
65. Speaker (abstract selected for oral presentation) at 43° Congresso Nazionale SIE (Società Italiana di Ematologia), Napoli, Italy, da 16 al 19 October 2011 (ECM);
66. Speaker at Theoretical and practical Stage on multiple myeloma in hematology division, Torino, Italy, dal 27 al 28 September 2011;
67. Speaker at Tavola Rotonda, Roma, Italy, 9 September 2011;
68. XI Congresso Nazionale SIES (Società Italiana di Ematologia Sperimentale), Torino, Italy, dal 6 al 8 October 2010;
69. Highlights from IMW and EHA, Torino, Italy, 6 October 2010;
70. Speaker at Il mieloma multiplo oggi. La pratica clinica con i nuovi agenti, Torino, 5 October 2010 (ECM);
71. Speaker at Neoplasie Ematologiche dell'Anziano e del paziente fragile, Torino 27 e 28 September 2010;
72. Immediate Life Support -ILS, Torino, Italy, il 14 May 2010, in qualità di discente (ECM);
73. Multiple Myeloma Debates 2010, Roma, Italy, 28-29 January 2010;
74. Speaker at I Approccio alla terapia del Mieloma nell'era dei nuovi farmaci, Padova, Italy, 19-20 November 2009;
75. Speaker (abstract selected for oral presentation) at 42° Congresso Nazionale SIE (Società Italiana di Ematologia), Milano, Italy, da 18 al 20 October 2009;
76. Speaker at La terapia del mieloma multiplo, esperienze a confronto, Bolzano, Italy, il 18 e 19 April 2008 (ECM);
77. Speaker (abstract selected for oral presentation) at 41° Congresso Nazionale SIE (Società Italiana di Ematologia), Bologna, Italy, dal 14 al 17 October 2007;
78. Corso "Mielodisplasie: diagnosi e classificazione", Torino, 21 June 2007;
79. Corso "How to treat: uso dei fattori di crescita in onco-ematologia", Torino, 12 April 2007;
80. Corso "Percorsi diagnostici-terapeutici nelle sindromi mieloproliferative croniche (SMPC)", Torino, 25 January 2007;
81. 2° Corso residenziale: Trapianto di Cellule Staminali emopoietiche, Firenze, dal 28 al 31 May 2006;
82. Advanced Trauma Life Support -ATLS Student Course of the American College of Surgeons, Dipartimento di Discipline Medico-Chirurgiche, Università di Torino, Torino, dal 21 al 27 October e il 2 November 2004;
83. PHTLS Advances Provider, Dipartimento di Discipline Medico-Chirurgiche, Università di Torino, Torino, 6-7 April 2001 in qualità di partecipante, durante il corso di studi in medicina.

#### Speaker - patient seminars

1. Collaborative Seminar, Myeloma Patients, Croatian Association with support of International Myeloma Foundation, Opatjia, Croatia, 26/10/2019.
2. Collaborative Seminar, Myeloma Patients, Italian Association Against Leukemia, Lymphomas and Myeloma (AIL), Torino, Italy, 16/02/2018.
3. 2ª Conferenza Nazionale sulle neoplasie ematologiche [2nd National Conference on Hematologic Neoplasms, Rome, 11/05/2017.
4. Collaborative Seminar, Myeloma Patients, Italian Association Against Leukaemia, Lymphomas and Myeloma (AIL), Milano, Italy, 27/09/2014.

Turin, March 27, 2020

Dr. Francesca Maria Gay